In addition, we validated our HFD obesity-NAFLD animal model by reporting significant increments in the rats’ final body and fat pad weights, fasting hyperglycemia, hyperlipidemia, hyperinsulinemia), higher HOMA-IR (a marker of IR), increases in the serum levels of ALT, AST, and GTT, and via the obvious degeneration and ballooning in the hepatocyte structure. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.